If you have been reading about copper(II) complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Three amino acids, histidine in the middle |
| Complex formula | C14H22CuN6O4 | One copper(II) ion per peptide |
| Molar mass (complex) | approx. 402.9 g/mol | Depends on counterion and hydration state |
| Appearance | Blue to blue-violet solid | Colour arises from copper coordination |
| Common synonyms | Copper tripeptide-1, GHK-Cu | Naming varies between disciplines |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
== Biography == Macleod was born in Clunie, near Dunkeld in Perthshire. Soon after he was born, his father Robert Macleod, a minister of the Free Church, was transferred to Aberdeen, where John attended Aberdeen Grammar School and enrolled in the study of medicine at the University of Aberdeen. At the University of Aberdeen, one of MacLeod's principal teachers was the young professor John Alexander MacWilliam. He was awarded his medical degree with honours in 1898 and then spent a year studying biochemistry at the University of Leipzig, Germany, on a travelling scholarship. He became a demonstrator at the London Hospital Medical School, where in 1902 he was appointed lecturer in biochemistry. In the same year, he was awarded a doctorate in public health from Cambridge University. Around that time he published his first research article, a paper on phosphorus content in muscles. In 1903, Macleod became a lecturer in physiology at the Western Reserve University in Cleveland, Ohio, where he remained for 15 years. This was the period when he developed an interest in carbohydrate metabolism that was to last for the rest of his career. In 1910, he delivered a lecture on various forms of experimental diabetes and their significance for diabetes mellitus at the joint meeting of the section on Pharmacology and Therapeutics and the section on Pathology and Physiology of the American Medical Association. In 1916, he was a Professor of Physiology at McGill University in Montreal, Canada.
=== Pentomic organization === In 1957, the division implemented the pentomic organization, officially Reorganization of the Airborne Division (ROTAD), to better prepare for tactical nuclear war in Europe. Five battle groups, each with a headquarters and service company, five rifle companies and a mortar battery, replaced the division's three regiments of three battalions each. The division's battle groups were:
==== Adaptive value ==== Cephalopods utilize chromatophores' color changing ability in order to camouflage themselves. Chromatophores allow coleoids to blend into many different environments, from coral reefs to the sandy sea floor. The color change of chromatophores works in concert with papillae, epithelial tissue which grows and deforms through hydrostatic motion to change skin texture. Chromatophores are able to perform two types of camouflage, mimicry and color matching. Mimicry is when an organism changes its appearance to appear like a different organism. The squid Sepioteuthis sepioidea has been documented changing its appearance to appear as the non threatening herbivorous parrotfish to approach unaware prey. The octopus Thaumoctopus mimicus is known to mimic a number of different venomous organisms it cohabitates with to deter predators. While background matching, a cephalopod changes its appearance to resemble its surroundings, hiding from its predators or concealing itself from prey. The ability to both mimic other organisms and match the appearance of their surroundings is notable given that cephalopods' vision is monochromatic. Cephalopods also use their fine control of body coloration and patterning to perform complex signaling displays for both conspecific and intraspecific communication. Coloration is used in concert with locomotion and texture to send signals to other organisms. Intraspecifically this can serve as a warning display to potential predators.
Reproductive disorders are thought to be caused by nutritional deficiencies, particularly zinc, iron, folate, and selenium deficiencies in coeliac disease. Coeliac disease often affects the liver, causing increased transaminase levels. This elevation of transaminases seen in coeliac disease is known as coeliac hepatitis. Mildly increased transaminases without symptoms and without other possible factors such as autoimmune or viruses that could cause liver abnormalities, characterise coeliac hepatitis. In patients with persistent symptoms despite treatments for coeliac disease, IgE-mediated allergic diseases, including food allergy, allergic rhinitis, and asthma, should be considered in the differential diagnosis, as they may coexist with celiac disease. Due to the systemic nature of coeliac disease and its potential to affect any organ, there are many rarer presentations of coeliac disease, some of which have an unclear relationship to the disease. Some of these more uncommon manifestations include peripheral neuropathy, epilepsy, psoriasis, recurrent aphthous stomatitis, pericardial effusion, and Lane-Hamilton syndrome.
Sources: en.wikipedia.org
== Related diseases == In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3, a massive altered composition of complex lipids occurs as a result of impaired mitochondrial fatty acid synthesis (mtFAS). For example, while the concentration of sphingomyelin is noticeably increased, the concentration of ceramides is proportionally decreased.
==== Reform policies ==== A broad range of interventionist reforms were introduced by the 1892–1895 Liberal government in areas such as housing, public health, and working conditions. Historian Walter L. Arnstein concludes:
A basic chestnut or "red" horse has a solid copper-reddish coat, with a mane and tail that is close to the same shade as the body coat. Sorrel is a term used by American stock horse registries to describe red horses with manes and tails the same shade or lighter than the body coat color. In these registries, chestnut describes the darker shades of red-based coats.
Sources: en.wikipedia.org
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.
The sequence was identified in human plasma in 1973. Early work examined its presence in blood and its proposed role in tissue repair. The copper-binding property was characterized afterward and became the focus of much later research.
The tripeptide has been measured in human plasma and other biological fluids. Whether it circulates mainly as the copper complex or as the free peptide remains an open question. Natural concentrations are low and difficult to measure reliably.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.